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ABSTRACT
Background. Endoscopic biliary drainage (EBD) and
percutaneous transhepatic biliary drainage (PTBD) are
both used to resolve jaundice before surgery for perihilar
cholangiocarcinoma (PHC). PTBD has been associated
with seeding metastases. The aim of this study was to
compare overall survival (OS) and the incidence of initial
seeding metastases that potentially influence survival in
patients with preoperative PTBD versus EBD.
Methods. Between 1991 and 2012, a total of 278 patients
underwent preoperative biliary drainage and resection of
PHC at 2 institutions in the Netherlands and the United
States. Of these, 33 patients were excluded for postopera-
tive mortality. Among the 245 included patients, 88 patients
who underwent preoperative PTBD (with or without pre-
vious EBD) were compared to 157 patients who underwent
EBD only. Survival analysis was done with Kaplan–Meier
and Cox regression with propensity score adjustment.
Results. Unadjusted median OS was comparable between
the PTBD group (35 months) and EBD-only group
(41 months; P = 0.26). After adjustment for propensity
score, OS between the PTBD group and EBD-only group
was similar (hazard ratio, 1.05; 95 % confidence interval,
0.74–1.49; P = 0.80). Seeding metastases in the laparo-
tomy scar occurred as initial recurrence in 7 patients,
including 3 patients (3.4 %) in the PTBD group and 4
patients (2.7 %) in the EBD-only group (P = 0.71). No
patient had an initial recurrence in percutaneous catheter
tracts.
Conclusions. The present study found no effect of PTBD
on survival compared to patients with EBD and no increase
in seeding metastases that developed as initial recurrence.
These data suggest that PTBD can safely be used in pre-
operative management of PHC.
Patients diagnosed with perihilar cholangiocarcinoma
(PHC) typically present with obstructive jaundice, which
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impairs liver function and is a risk factor for mortality after
hepatobiliary surgery.1 Preoperative biliary drainage can
resolve jaundice before surgery and may help reduce
perioperative morbidity in patients submitted to en bloc
partial hepatectomy.2 In Western centers, patients are
preoperatively treated with endoscopic biliary drainage
(EBD), percutaneous transhepatic biliary drainage (PTBD),
or both.
PTBD has been the preferred preoperative drainage
method in Asian centers for decades, with favorable peri-
operative morbidity and mortality rates, but recent studies
have focused on seeding metastases after preoperative
PTBD and resection.3–5 These seeding metastases pre-
sumably result from exfoliated tumor cells in bile that
drains along the percutaneous catheter. The incidence of
catheter tract recurrences in those studies ranged from 2 to
5 %, and the incidence of laparotomy scar recurrences was
1.3 %.6–9 A low rate of seeding metastases has been
reported since the early years of preoperative PTBD, but it
is only recently that this low rate has been used to advocate
for an exclusively endobiliary strategy.10,11 On the basis of
the above data, many Eastern authors recently suggested
that preoperative PTBD should be avoided and that endo-
scopic nasobiliary drainage should be preferred.12–14 From
an oncologic perspective, however, only recurrences that
affect overall survival (OS) are clinically relevant recur-
rences. It remains unclear if the reported seeding
metastases were solitary recurrences, if they coincided with
other recurrences, or if they developed after recurrent
metastatic disease. Moreover, none of the above studies
have assessed the effect of preoperative PTBD on OS.
The present study was designed to assess OS after
resection of PHC in patients with preoperative PTBD
compared to patients with preoperative EBD. Additionally,
we assessed the incidence of seeding metastases develop-
ing as initial recurrence after resection because we assumed
that these initial recurrences would potentially influence
OS. The broader objective was to establish the role that
PTBD should have in preoperative management of PHC:
either as a drainage method that can safely be used or only
as a salvage procedure when other methods have failed.
METHODS
Study Population
Consecutive patients who underwent a resection with
curative intent for PHC were identified from prospectively
maintained databases at the Academic Medical Center
(AMC) in Amsterdam, the Netherlands, and the Memorial
Sloan Kettering Cancer Center (MSKCC), New York. PHC
was defined according to the 7th edition of the American
Joint Committee on Cancer staging manual.15 Patients
were included from 1991 to 2012 if they had undergone
preoperative biliary drainage before resection of PHC
using extrahepatic bile duct resection and reconstruction
with or without concomitant liver resection. Exclusion
criteria were R2 resection, repeat resection after initial
resection at another hospital, and 90 day postoperative
mortality. Additional data were collected through retro-
spective chart review. The institutional review board at
both institutions approved this study.
Patient selection for resection and preoperative man-
agement was similar between the 2 centers, as described
previously.16 Biliary drainage was initiated in either a
regional center before referral, or after referral to AMC or
MSKCC. Patients were treated with initial EBD or initial
PTBD according to the treating physician’s preference.
Additional preoperative PTBD was performed when biliary
decompression was inadequate after EBD or if EBD was
associated with complications, such as cholangitis. The
PTBD group in this study included patients treated with
initial PTBD and patients treated with additional PTBD
after inadequate EBD. The control group consisted of
patients treated with preoperative EBD without previous or
subsequent PTBD.
All patients in the AMC in Amsterdam were routinely
treated with a preoperative low-dose irradiation protocol
(3 9 3.5 Gy in the 3 days before the resection) with the
aim of preventing seeding metastases.17 Entry sites of
percutaneous drain tracts in the abdomen were not rou-
tinely excised after resection.
Follow-up After Resection
All patients were followed with CT imaging at 3 and
6 months after resection to detect early recurrence.
Thereafter, patients at AMC were followed with clinical
assessments until 5 years after resection; imaging was
performed when indicated by rising tumor markers,
symptoms, or findings at physical examination. At
MSKCC, follow-up included CT or MRI imaging every 4
to 6 months. Pathologic confirmation of recurrences was
often obtained, but it was not required if imaging unam-
biguously demonstrated recurrent disease in patients who
were unfit to undergo further treatment. Suspect lesions at
the laparotomy scar or in the prior PTBD drainage tract
were always confirmed with a biopsy.
Outcomes
The primary end point in this study was OS, measured
from the date of surgery to the date of death. Patients alive
at follow-up were censored at the date of last contact before
April 1, 2014. We used propensity score method rather
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than traditional multivariable analysis because this method
is considered superior in reducing confounding and bias,
especially when analyzing relatively small observational
data sets.18,19
Secondary end points were directed toward the inci-
dence of seeding metastases after resection. Analysis of
recurrences focused on the pattern of initial recurrences
based on the assumption that prognosis was unlikely to be
affected by seeding metastases that arose after recurrence
at another site. Seeding metastases were defined as recur-
rences either in the percutaneous catheter tract (i.e., any
recurrence along the catheter tract from skin to the intra-
hepatic bile duct) or in the laparotomy scar (i.e., any
recurrence in the abdominal wall at the laparotomy scar).6,8
In addition, the incidence of peritoneal recurrences (i.e.,
intra-abdominal recurrence in the peritoneum or ascites
with malignant cells) was assessed, although these recur-
rences were not necessarily regarded as seeding metastases.
Statistical Analyses
Our method of propensity score adjustment was
straightforward. First, we estimated propensity scores for
the probability of PTBD assignment on the basis of all
observed baseline characteristics. Second, we analyzed OS
with a Cox proportional hazards model including 2 vari-
ables: drainage method (PTBD vs. EBD only) and
propensity score (continuous variable). This model adjusts
the survival analysis conditional on the propensity score.
Thus, the model calculates the effect of PTBD compared to
EBD only given that the propensity scores (i.e., the
observed baseline characteristics) are hold equal.
In more detail, we calculated propensity scores using
multivariable logistic regression with preoperative PTBD
as the outcome of interest and with adjustment for observed
baseline characteristics, including demographics, comor-
bidities, total bilirubin level at referral, the level of bile
duct involvement (Bismuth class), preoperative imaging
variables (Blumgart T stage), cholangitis, extended hepa-
tectomy, and treating center. Three baseline characteristics
had missing data, including bilirubin level at presentation
(27.8 % missing), Blumgart T stage (6.9 % missing), and
preoperative cholangitis (5.3 % missing). To avoid bias,
multiple imputation with 10 imputed data sets was per-
formed for these missing data before estimation of the
propensity scores, using a regression model that included
all baseline characteristics. To evaluate residual bias after
adjustment for propensity score, logistic regressions with
drainage method as outcome were performed for each of
the baseline characteristics with and without adjustment for
propensity scores. We then estimated OS using the
Kaplan–Meier method, and compared the groups with
the log-rank test in univariable analysis. Finally, a
multivariable Cox proportional hazards model was used to
compare OS between the PTBD and EBD-only groups after
adjustment for the propensity score as a continuous vari-
able. To assess the proportional hazards assumption, we
inspected the hazard ratio plots and found no violation.
Analysis of secondary end points was performed by v2
tests, and 95 % confidence intervals (CIs) were determined
using the standard deviation of the mean. The type of liver
resection and pathologic characteristics were also com-
pared by v2 tests. All analyses were performed in SPSS v22
(IBM, Armonk, NY).
RESULTS
Patients
A total of 344 consecutive patients underwent resection
of PHC during the study period, of whom 66 (19.2 %) were
excluded because they had not undergone preoperative
biliary drainage. Of the remaining 278 patients, 33
(11.9 %) were excluded for 90 day postoperative mortal-
ity: 3 (8.1 %) of 37 patients treated with preoperative
PTBD; 17 (9.8 %) of 147 patients treated with preoperative
EBD; and 13 (19.4 %) of 67 patients treated with both. As
a result, 245 patients were included, comprising 128 treated
at MSKCC and 117 at AMC. Patient characteristics were
not different between MSKCC and AMC, except for older
age at MSKCC (mean age 65 vs. 61, respectively). The
policy to use preoperative PTBD was different between the
centers: PTBD was more often used in MSKCC than in
AMC (43.8 vs. 27.4 %, respectively; P = 0.008).
The PTBD group consisted of 88 patients (36 %) who
were treated with preoperative PTBD, including 54 patients
who underwent PTBD after inadequate EBD. Patients in
the PTBD group had undergone a median of 2 preoperative
PTBD procedures (range 1–5). The median time between
the first PTBD drainage procedure and surgery was 38 days
(range 3–262); 17 patients (19.3 %) had a percutaneous
catheter in situ more than 60 days. The EBD-only group
(i.e., the control group) consisted of 157 patients (64 %)
who were treated with preoperative EBD without PTBD.
The distribution of patients between the PTBD and EBD-
only groups was equal throughout the study period. The
percentage of PTBD procedures between 1991 and 1996
was 32.3 %; 1997 and 2001, 37.0 %; 2002 to 2006,
32.7 %; and 2007 to 2012, 38.2 % (P = 0.88).
Baseline characteristics of the study groups are pre-
sented in Table 1. Nearly all variables were different
between groups, indicating severe bias at baseline. The
mean ± standard deviation propensity scores for patients
in the PTBD and EBD-only groups were 0.53 ± 0.24 and
0.27 ± 0.19, respectively, with an area under the curve of
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0.79. Only minimal differences in baseline characteristics
remained after adjustment for propensity score, as indi-
cated by the adjusted P values in Table 1. Type of
resection and pathologic characteristics of both study
groups are shown in Table 2.
Overall Survival
Among the 245 included patients, 173 patients (71 %) died
during follow-up. The median OS was 38 months (95 % CI
32–44), and 5-year survival was 32 %. Median follow-up
among survivors was 52 months (range 6–251 months).
The unadjusted OS was comparable between the PTBD
group (36 months) and the EBD-only group (41 months;
P = 0.25; Fig. 1a). Stratifying patients in the PTBD group
between those who underwent EBD plus PTBD and those
who underwent PTBD only did not reveal a difference
when these 2 groups were compared to patients who
underwent EBD only (P = 0.44; Fig. 1b). After using
propensity score adjustment to account for potential con-
founders, OS between the PTBD group and EBD-only
group was similar (adjusted hazard ratio, 1.05; 95 % CI
0.74–1.49; P = 0.80; Fig. 2).
Seeding Metastases Developing as Initial Recurrence
A total of 87 patients in the PTBD group and 147
patients in the EBD-only group were available for recur-
rence analysis (1 patient missing in the PTBD group and 10
patients missing in the EBD-only group; total 4 %).
Seeding metastases occurred as initial recurrence in 3
(3.4 %) of 87 patients in the PTBD group (95 % CI 0–7.3),
and in 4 (2.7 %) of 147 patients in the EBD-only group
(95 % CI 0–5.3; P = 0.71). Among the total 7 patients who
developed a seeding metastasis, 3 had developed a con-
current local recurrence. Time to diagnosis of the seeding
metastases was 8, 13, 14, 17, 20, 21, and 66 months (me-
dian, 17 months), and OS in these 7 patients was 13, 30, 20,
21, 21, 27, and 142 months (median, 21 months), respec-
tively. All 7 seeding metastases developing as initial
recurrence were abdominal wall recurrences at the site of
the laparotomy scar. No initial recurrences were observed in
TABLE 1 Baseline characteristics
Variable PTBD (n = 88) EBD only (n = 157) P
Imputed Imputed adjusted for
propensity score
Male 53 (60.2) 100 (63.7) 0.59 0.94
Age, y, median (IQR) 61 (16) 65 (13) 0.01 0.99
Comorbidity, Charlson score ,27 median (IQR) 0 (1) 0 (1) 0.92 0.81
Total bilirubin at referral, lmol/L, median (IQR) 135 (231) 39 (67) 0.02 0.92
Bismuth class on imaging 0.001 0.95
Type 1 8 (9.1) 41 (26.1)
Type 2 11 (12.5) 23 (14.6)
Type 3a 30 (34.1) 44 (28.0)
Type 3b 18 (20.5) 28 (17.8)
Type 4 19 (21.6) 16 (10.2)
Left or right hepatic duct 2 (2.3) 5 (3.2)
Blumgart T stage on imaging 0.004 0.96
1 38 (43.7) 86 (61.0)
2 28 (32.2) 40 (28.4)
3 21 (24.1) 15 (10.6)
Preoperative cholangitis 25 (29.4) 13 (8.8) \0.001 0.89
Extended hepatectomy 43 (48.9) 44 (28.0) 0.001 0.99
Treating center 0.008 0.98
MSKCC 56 (43.8) 72 (56.3)
AMC 32 (27.4) 85 (72.6)
Data are presented as n (%) unless otherwise specified. Logistic regressions with drainage method as outcome (PTBD or EBD only) were
performed for each of the baseline variables to evaluate residual bias after adjustment for propensity scores
PTBD percutaneous transhepatic biliary drainage, EBD endoscopic biliary drainage, IQR interquartile range, MSKCC Memorial Sloan Kettering
Cancer Center, AMC Academic Medical Center
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TABLE 2 Type of liver resection and pathologic characteristics
Characteristic PTBD (n = 88) EBD only (n = 157) P
Preoperative cytology assessment, n (%) 0.40
Positive or suspicious 49 (55.7) 93 (59.2)
Negative 18 (20.4) 39 (24.8)
Not performed 21 (23.9) 25 (15.9)
Type of liver resection, n (%) 0.003
Extrahepatic bile duct resection only 10 (11.4) 38 (24.2)
Segment 4/5 wedge resection 3 (3.4) 17 (10.8)
Mesohepatectomy 2 (2.3) 0 (0)
Left hemihepatectomy 22 (25.0) 34 (21.7)
Left extended hemihepatectomy 8 (9.1) 12 (7.6)
Right hemihepatectomy 5 (5.7) 17 (10.8)
Right extended hemihepatectomy 38 (43.2) 39 (24.8)
Resection including caudate lobea 46 (61.3) 63 (61.8) 0.08
Resection specimen, n (%)
T3 or T4 tumor (AJCC 7th edition) 34 (38.6) 31 (19.7) 0.002
R1 resection 21 (23.9) 49 (31.2) 0.24
Moderate/poor differentiation 22 (25.0) 33 (21.0) 0.52
Perineural invasion 70 (79.5) 108 (68.8) 0.08
Resected lymph nodes
Total lymph node count, median (range) 3 (1–22) 4 (1–20) 0.15
N1 lymph node metastasis, n (%) 30 (34.1) 35 (22.3) 0.05
Mean lymph node ratio (positive/negative) 0.14 (1/7) 0.09 (1/11) 0.03
PTBD percutaneous transhepatic biliary drainage, EBD endoscopic biliary drainage, AJCC American Joint Committee on Cancer
a Percentage of caudate resections only concerns patients who underwent meso- or hemihepatectomy
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FIG. 1 Unadjusted Kaplan–Meier survival plots. a Patients in PTBD
and EBD-only groups had comparable survival (P = 0.26). b Strat-
ifying patients in PTBD group between those who underwent PTBD
only and those who underwent PTBD plus EBD did not reveal
difference (P = 0.45)
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a percutaneous catheter tract. The incidence of seeding
metastases was not significantly different between both
centers: 5 (3.9 %) of 128 patients at MSKCC (95 % CI
0.5–7.3) and 2 (1.9 %) of 106 patients at AMC (95 % CI
0–4.5; P = 0.46).
Peritoneal Recurrences
Initial peritoneal recurrences were observed in 32
(13.7 %) of 234 patients with available recurrence status
(95 % CI 9.2–18.1). These included 11 (12.6 %) of 87
patients in the PTBD group and 21 (14.3 %) of 147 patients
in the EBD-only group, which was not significantly dif-
ferent between groups (P = 0.85). Concomitant peritoneal
recurrence was observed in only 1 of 7 patients with a
seeding metastasis as initial recurrence.
DISCUSSION
Biliary drainage has become an important component of
the preoperative preparation of patients with PHC, as
multiple studies have shown that it decreases postoperative
liver failure and mortality.2 Nonetheless, several contro-
versies have evolved. Eastern centers reported catheter
tract recurrences after preoperative PTBD and resection of
PHC and promoted the use of alternative drainage methods.
In the present study, however, we showed that preoperative
PTBD is not associated with survival after resection of
PHC compared to patients who underwent preoperative
endoscopic drainage. Moreover, PTBD was not associated
with an increase in seeding metastases developing as initial
recurrence that would potentially affect survival.
One previous study has assessed survival after preop-
erative PTBD: in a study of 141 patients with resected
PHC, Hirano et al. found a median OS of 31 months after
preoperative PTBD compared to 59 months after preoper-
ative EBD.20 The authors attributed this difference to an
increase in peritoneal metastases after preoperative PTBD.
However, the PTBD group in that study had more
advanced disease as evidenced by more patients with
Bismuth type 4 tumors (30 vs. 14 %), more perioperative
blood transfusions (31 vs. 9 %), and more frequent hepatic
artery resections (22 vs. 9 %). Although a survival differ-
ence was confirmed in multivariable analysis, the statistical
model in that study may have been at risk to a false-posi-
tive finding due to overfitting because it was adjusted for 9
other covariates. Moreover, statistical criteria, like adjust-
ing for all significant variables from univariable analysis,
as used in the study by Hirano et al., are considered
insufficient to characterize confounding or selection bias.21
Catheter tract recurrences have been reported in a range
of 2 to 5 % after preoperative PTBD, but our study found
no catheter tract recurrence developing as the initial
recurrence after resection.6–9 This discrepancy may be
partly explained by the behavior of seeding metastases.
Apparently, catheter tract recurrences, if they occur at all,
have a tendency to grow slowly and not to manifest before
other recurrences have been diagnosed. Alternatively, dif-
ferences in management and patient selection between
centers in the present study and Eastern centers could
explain the discrepancy. The duration of PTBD has been
identified as a risk factor for catheter tract recurrences:
preoperative PTBD longer than 60 days was associated
with an increased risk in the study by Takahashi et al., and
more than 25 % of the patients in that study reached the
cutoff, compared to only 19 % in the present study.6 It is
uncertain whether preoperative low-dose radiotherapy,
which was standard treatment in the AMC and not in
MSKCC, has prevented catheter tract recurrences or other
seeding metastases. There was no difference in the inci-
dence of seeding metastases between the 2 study centers, so
the current data does not support routine use of preopera-
tive radiotherapy.
Normally, PHC spreads to the liver and through lymph
nodes to the abdomen or extra-abdominal sites.22 In anal-
ogy to previous studies, we named recurrences in the
laparotomy scar or in the percutaneous catheter tract
‘‘seeding metastases’’ because these recurrences show a
deviating pattern from normally observed recurrences and
are likely the result of tumor seeding. Nonetheless, clear
evidence for a role of seeding tumor cells has not been
demonstrated in these kinds of recurrences. Alternatively,
local inflammation after surgical trauma might naturally
attract circulating tumor cells.23 To a larger extent, peri-
toneal recurrences are doubtfully the result of tumor
seeding. Although some peritoneal metastases may be
caused by perioperative tumor seeding and could thus be
preventable, most peritoneal metastases will reflect
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FIG. 2 Survival plot after adjustment for propensity score in Cox
regression analysis showing similar OS in PTBD and EBD-only
groups (P = 0.80)
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extensive disseminated disease. In the present study, pre-
operative PTBD did not increase the incidence of
peritoneal recurrences.
This retrospective study has several limitations. The
sample size was likely insufficient to definitively exclude
an adverse effect of preoperative PTBD on OS after
resection of PHC. Although no statistically significant
difference was found when comparing unadjusted OS and
propensity-adjusted OS, the 95 % CI of the propensity-
adjusted hazard ratio was still relatively wide. However,
not a single catheter tract recurrence was found during
follow-up of initial recurrences, and the incidence of initial
abdominal wall recurrences was also similar between the
PTBD and EBD-only groups.
The analysis of seeding metastases as initial recurrence
requires 3 comments. First, follow-up was not standard-
ized, so it is possible that some initial seeding metastases
were missed after patients were lost to follow-up. Second,
we only recorded initial recurrences, and we may have
missed seeding metastases that occurred after initial diag-
nosis of recurrent disease. This follow-up approach may
not provide the true incidence of seeding metastases, but it
is based on clinical meaningfulness: management or OS is
unlikely to be affected by seeding metastases if they occur
late in the course of the disease, after the initial diagnosis
of recurrence. Third, the present study included only
patients who underwent a potentially curative resection, so
patients with inoperable disease due to (extra)hepatic or N2
lymph node metastases were excluded. On the basis of
these data, we cannot be sure whether some patients had
seeding metastases at the time of surgery. Nonetheless, in
our experience with management of PHC, we have never
observed any seeding metastases during exploratory
laparotomy.
Regarding management of PHC, the use of preoperative
drainage before smaller liver resections (e.g., left hemi-
hepatectomy) may not be necessary because of the large
liver remnant. Moreover, preoperative drainage could even
be harmful in these patients, as a recent study showed that
preoperative drainage might increase perioperative mor-
bidity due to infection-related complications.24 In the
present study, preoperative drainage was often used before
small liver resections because many patients present to our
centers with drains already in place or with badly placed
drains that are associated with infection and require revi-
sion. Of note, 48 extrahepatic bile duct resections without
liver resection were performed for Bismuth type 1 or 2
tumors during the early years of the study cohort. Since
approximately 2000, a liver resection is part of a poten-
tially curative resection for PHC, particularly for Bismuth
type 2.
Preoperative PTBD for PHC is currently being used in
most Western surgical specialty centers when EBD fails to
obtain adequate preoperative biliary drainage. Some cen-
ters even prefer to use preoperative PTBD as primary
drainage method instead of EBD. There are many reasons
to use PTBD: it has been associated with fewer preopera-
tive complications than EBD; percutaneous catheters
provide direct access to bile ducts perioperatively; and
percutaneous catheters can be used as stents to protect
hepaticojejunostomies from leaking postoperatively.25 No
definitive data are currently available for any of the sug-
gested advantages, but a randomized controlled trial is
being conducted to assess differences in perioperative
complications between EBD and PTBD.26
In conclusion, these data suggest that PTBD can safely
be used in preoperative management of PHC. The present
study found no effect of PTBD on survival compared to
patients who underwent preoperative EBD and no increase
in seeding metastases that develop as initial recurrence.
The decision to use preoperative PTBD should not be
influenced by concerns about catheter tract recurrences;
they are very rare, and they probably do not affect OS.
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